World Market for Psychotherapeutic Drugs Closes in on $50 Billion in Sales

[Soory bouth that, forgot the URL].

http://digital50.com/news/items/PR/2...-and-adhd.html

World Market for Psychotherapeutic Drugs Closes in on $50 Billion in
Sales

NEW YORK, Jan. 18 /PRNewswire/ -- Based on the steadily increasing
success of current drugs on the market as well as the potential
success of
numerous drugs currently in late stage development or awaiting
regulatory
approval, sales of psychotherapeutic drugs treating everything from
schizophrenia and depression to ADHD and anxiety are expected to reach
nearly $50 billion by 2010, according to a new report from life
science
research firm Kalorama Information.
The World Market for Psychotherapeutic Drugs, the most exhaustive
guide
to this booming market, shows 2005 revenues checking in at $35.7
billion,
up 3.9% over 2004. The report anticipates new products bringing in an
additional $6.3 billion by 2010 increasing the competitive outlook in
many
segments.
Antipsychotics and antimanics along with antidepressants make up
the
lions share of worldwide sales accounting for nearly 80% of the
market.
Sales of antianxiety drugs, ADHD stimulants and nonstimulants, and
other
psychotherapeutic drugs segments rounded out the mix of remedies to
treat a
remarkably under-treated global incidence of mental illness.
In fact, the U.S. accounts for more than 62% of worldwide sales as
in
many parts of the world there is still a negative view and stigma
surrounding mental health issues. In contrast, Japan accounts for only
2%
of global sales.
"The potential market is definitely worth billions more than the
current market where many regions suffer from a lack of education,
mental
health policy, and services to evaluate and treat mental health
patients,"
notes Melissa Elder, the report's author. "Despite these global
inadequacies, there are extremely promising drugs in the pipeline that
should have a tremendous impact on this industry within the next few
years."
The World Market for Psychotherapeutic Drugs provides a historical
market overview, including condition statistics and market forecasts
for
each of the major psychotherapeutic segments. It also includes
in-depth
company profiles of emerging competitors and leaders in the field, and
profiles of drugs in the pipeline with expected approval status and
implications for their impact on the market. It can be purchased
directly
from Kalorama Information by visiting
http://www.kaloramainformation.com/P...-Drugs-1340128. It
is
also available at MarketResearch.com.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies
the
latest in independent market research for the life sciences. For more
information, contact Tom Ehart at 240-747-3014 or
, or visit
http://www.KaloramaInformation.com.